Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00003072-199805000-00021 | DOI Listing |
Ann Nucl Med
November 2010
Department of Nuclear Medicine, University of Patras Medical School, University Hospital of Patras, Rion, Patras, Greece.
Objective: Previous studies have demonstrated the feasibility of targeting lymphoma lesions with somatostatin receptor binding agents, mainly with In-111-pentetreotide. In the present work another somatostatin analog, Tc-99m depreotide, is investigated.
Methods: One-hundred and six patients, 47 with Hodgkin's (HL) and 59 with various types of non-Hodgkin's lymphoma (NHL), were imaged with both Tc-99m depreotide and Ga-67 citrate.
Clin Nucl Med
July 2002
Nuclear Medicine Department, Royal Brisbane Hospital, Herston, Queensland, Australia.
Clin Nucl Med
January 2002
Department of Nuclear Medicine, Numune Hospital, Ankara, Turkey.
Clin Nucl Med
May 1998
Department of Nuclear Medicine, The Athens Chest Hospital Sotiria, Greece.
Clin Nucl Med
December 1993
Department of Nuclear Medicine & Ultrasound, Westmead Hospital, NSW, Australia.
A 69-year-old woman presented with non-Hodgkin's lymphoma of the right ilioinguinal region in whom bilateral uptake of Ga-67 in hilar lymph nodes was noted on thoracic SPECT. There were no Ga-67 abnormalities elsewhere within the thorax, and a chest CT scan was also normal. The patient received radiotherapy to the inguinal region and remained in clinical remission for 28 months following treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!